Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Nataliia Kravchenko (Dniepropetrovsk, Ukraine), Nataliia Kravchenko, Tetyana Pertseva, Tetyana Kireyeva. Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP). Eur Respir J 2016; 48: Suppl. 60, 2588

Member's Comments

No comment yet.

Related content which might interest you: Serum C-reactive protein (CRP) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 241s Year: 2004 C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 545s Year: 2005 C-reactive protein (CRP) utility in severe community-acquired pneumonia (SCAP) prognosis Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia Source: Eur Respir J 2005; 25: 688-692 Year: 2005 Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP) Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment Year: 2013 High serum procalcitonin and C-reactive protein levels can exclude tuberculosis in community-acquired pneumonia patients with atypical presentation Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 C-reactive protein (CRP) as a marker of disease severity in community acquired pneumonia patients with sepsis Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012 Diagnostic accuracy of lipopolysaccharide-binding protein (LBP), fibrinogen and C-reactive protein (CRP) in differentiating pneumonia from acute bronchitis in primary care Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008 Serum procalcitonin and C-reactive protein in children with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 488s Year: 2006 C-reactive protein (CRP), an early prognostic tool in community acquired pneumonia (CAP) Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia Year: 2009 Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 C Reactive Protein (CRP), procalcitonin (PCT) and proadrenomedullin (Pro-ADM), as markers to discriminate bacterial, viral and mixed community acquired pneumonia (CAP) Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 C-reactive protein (CRP) at admission: is it really usefull in COVID-19 pneumonia? Source: Virtual Congress 2021 – COVID - 19 biomarkers Year: 2021 Surfactant protein D (SPD) and C-reactive protein (CRP) in patient with low respiratory tract infections (LRTI) Source: Annual Congress 2013 –Lung infections: a clinical point of view Year: 2013 Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases Year: 2014 Prognosis value of initial C-reactive protein (CRP) assay in patients with community acquired pneumonia Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention Year: 2008 Serum procalcitonine (PCT) as a marker of respiratory infection by pseudomonas aeruginosa (PA) in patients with COPD or bronchiectasis Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia Source: Eur Respir J 2008; 32: 726-732 Year: 2008